Experimental hepatitis b drug shows promise but study halted early
NCT ID NCT02065336
First seen Jan 15, 2026 · Last updated May 25, 2026 · Updated 17 times
Summary
This study tested a new drug called ARC-520, given with the standard medicine entecavir, to see if it could lower hepatitis B virus levels in people with chronic infection. The trial included 58 adults with different types of chronic hepatitis B. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site 1
Pokfulam, Hong Kong
-
Research Site 2
Shatin, Hong Kong
Conditions
Explore the condition pages connected to this study.